Вы можете подобрать другие интересные события в нашем календаре, или воспользоваться поиском:
Вашингтон, США 5 – 8 июня / 2012
Получите билет на выставку. Выберите необходимое количество билетов, заполните короткую форму и получите билеты на e-mail.
|Бесплатно||− 1 +||$0|
К сожалению, билеты закончились, но у нас есть другие выставки, которые вы можете посетить.
Это мероприятие уже закончилось.
Following the aftermath of the H1N1 pandemic of 2009, the U.S. Department of Health and Human Services (HHS) initiated a comprehensive review of the U.S. Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) in order to move towards “modernized countermeasure production process where we have more promising discoveries, more advanced development, more robust manufacturing, better stockpiling, and more advanced distribution practices.” The vision articulated by the review presented a new strategy to enhance the Nation’s ability to counter an attack or other threat to public health.
Additional, the Pandemic and All-Hazards Preparedness Act (PAHPA), which established BARDA as the focal point within HHS for the advanced development and acquisition of MCMs against CBRN and naturally occurring threats, is up for reauthorization by Congress this year. While the Act has strengthened the Nation’s public health preparedness response, as demonstrated during the H1N1 pandemic, challenges remain including the advent of new emerging infectious diseases, there is still work to be done and PAHPA is important to continued research and development.
In response, the annual Biodefense Vaccines & Therapeutics conference, scheduled for July 20-22, 2011, will once again provide the latest information on the Federal government’s chemical, biological, radiological and nuclear (CBRN) medical countermeasures (MCM) research, development and procurement initiatives, and insights into potential legislative changes and its potential impact on the biodefense industry. The conference is the ideal venue to interact face-to-face with representatives from Federal agencies tasked with building the CBRN MCMs capacity in the United States. Year after year, the conference brings together the community to explore strategies with dealing with various challenges, share perspectives on dealing with uncertainty and establish fruitful collaboration to further the development of needed biological, chemical, radiological and nuclear (CBRN) medical countermeasures.
The 2011 conference will include the Developments in Biodefense Technology Platforms Symposium, July 20, 2011, where leading researchers from government, industry and academia will provide a briefing on the latest platforms being developed in biodefense and how these innovations are being used to address threats from emerging infectious diseases.
Building on the 2010 Animal Models Forum, the 2011 conference will include the Animal Model and Regulatory Science Workshop, which will highlight the FDA’s regulatory science initiatives and efforts underway on the Draft Guidance for Animal Rule. The workshop will also feature case studies of ongoing animal efficacy studies for MCMs, including smallpox, anthrax, plague and tularemia to name a few. The forum will facilitate the sharing of ideas and experience among USG, academia and industry on animal model development, and the application of Animal Rule regulatory science in advancing MCM development.